MYC and breast carcinoma: Targeting c-MYC opens up new possibilities for therapeutic intervention, especially with the development of nanoparticle-mediated drug delivery strategies as revealed by αvβ3 integrin-nanoparticole-mediated drug delivery of a c-MYC inhibitor in breast cancer [125].